X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
Under the agreement, Coya granted Dr. Reddy’s an exclusive license to commercialize COYA 302, a proprietary co-pack kit containing combination of low dose interleukin-2 and CTLA-4 Ig (abatacept) for the treatment of Amyotrophic Lateral Sclerosis.
Lead Product(s): Interleukin 2,Abatacept
Therapeutic Area: Neurology Product Name: COYA 302
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Dr. Reddy\'s Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 06, 2023
Details:
Ceplene® demonstrated a clinical interest in maintenance treatment of acute myeloid leukemia (AML) in patients below 60 years of age in first "complete remission" (symptom-free period of disease after initial treatment) in a clinical study.
Lead Product(s): Histamine Dihydrochloride,Interleukin 2
Therapeutic Area: Oncology Product Name: Ceplene
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Delbert Lab
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 18, 2022
Details:
AB-101, an ADCC enhancer NK-cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers. Artiva is currently advancing a Phase 1/2 of AB-101 in combination with rituximab for the treatment of relapsed or refractory B-cell lymphomas.
Lead Product(s): AB-101,Rituximab,Interleukin 2
Therapeutic Area: Oncology Product Name: AB-101
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
Preliminary results from the full analysis set (FAS) showed that at week 52, patients who received RC-18 (telitacicept) had a significantly higher rate of SRI-4 (The Systemic Lupus Erythematosus Responder Index 4) response than those who received placebo.
Lead Product(s): Telitacicept,Interleukin 2
Therapeutic Area: Immunology Product Name: RC-18
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2022
Details:
GEN-011 is a neoantigen-targeted peripherally derived T cell therapy candidate comprised of autologous CD4+ and CD8+ T cells that are specific for up to 30 ATLAS-identified neoantigens to limit tumor escape.
Lead Product(s): GEN-011,Interleukin 2,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: GEN-011
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
GEN-011 is a neoantigen-targeted peripherally derived T cell therapy candidate comprised of autologous CD4+ and CD8+ T cells that are specific for up to 30 ATLAS-identified neoantigens to limit tumor escape.
Lead Product(s): GEN-011,Interleukin 2,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: GEN-011
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
IOV-2001, non-Genetically Modified Autologous PBL product, showed activity against autologous leukemia cancer cells in preclinical studies is now under investigation in the treatment of CLL or SLL.
Lead Product(s): IOV-2001,Interleukin 2
Therapeutic Area: Oncology Product Name: IOV-2001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2021
Details:
The Committee voted on three questions presented by the FDA on whether the efficacy data support approval of avacopan for the treatment of adult patients with AAV, safety profile of avacopan and benefit-risk profile of the product.
Lead Product(s): Avacopan,Interleukin 2
Therapeutic Area: Immunology Product Name: CCX168
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2021
Details:
Artiva’s pipeline includes AB-101, an ADCC enhancer NK-cell therapy which is currently under Phase 1/2 clinical trial in combination with rituximab for the treatment of relapsed or refractory B-cell lymphomas.
Lead Product(s): AB-101,Rituximab,Interleukin 2
Therapeutic Area: Oncology Product Name: AB-101
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Venrock Healthcare Capital
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing February 26, 2021
Details:
These funds will allow the Company to complete the expansion of its Multikine* (Leukocyte Interleukin, Inj.) cancer immunotherapy manufacturing facility near Baltimore, MD in anticipation of BLA submission and subsequent marketing approval.
Lead Product(s): Interleukin 2
Therapeutic Area: Oncology Product Name: Multikine
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Warrant Exercises June 30, 2020
Details:
Study aimed at evaluating the safety and efficacy of TIL therapy in metastatic NSCLC (mNSCLC) after evidence of progression on nivolumab.
Lead Product(s): Interleukin 2,Tumor infiltrating lymphocyte,Nivolumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2020
Details:
CEL-SCI has reached the targeted threshold of 298 events required to conduct the data evaluation for its pivotal Phase 3 head and neck cancer study of Multikine immunotherapy.
Lead Product(s): Interleukin 2
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2020
Details:
Company's pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine meets safety and efficacy criteria of the ongoing Phase 3 study concluded by IDMC.
Lead Product(s): Interleukin 2
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2020
Details:
CEL-SCI intends to use the net of the offering to fund the continued development of Multikine, LEAPS and for other general corporate purposes.
Lead Product(s): Interleukin 2
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Aegis Capital Corp
Deal Size: $7.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
